Hiroyuki Kato, Ph.D., M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatocyte Nuclear Factor 1-beta | 1 | 2021 | 94 | 0.870 |
Why?
|
| Biliary Tract | 2 | 2019 | 139 | 0.740 |
Why?
|
| Tooth Extraction | 1 | 2020 | 215 | 0.700 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2021 | 483 | 0.660 |
Why?
|
| Carcinoma, Pancreatic Ductal | 3 | 2022 | 1506 | 0.620 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2020 | 678 | 0.590 |
Why?
|
| Gallbladder | 1 | 2016 | 307 | 0.530 |
Why?
|
| Pancreatic Ducts | 1 | 2016 | 334 | 0.510 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2020 | 1671 | 0.470 |
Why?
|
| Surgical Instruments | 1 | 2015 | 411 | 0.460 |
Why?
|
| Homeodomain Proteins | 1 | 2021 | 2457 | 0.440 |
Why?
|
| Pancreatic Neoplasms | 3 | 2022 | 5000 | 0.370 |
Why?
|
| Wound Healing | 1 | 2020 | 2797 | 0.340 |
Why?
|
| Fractures, Bone | 1 | 2020 | 1867 | 0.340 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2021 | 2085 | 0.340 |
Why?
|
| Stomach Neoplasms | 1 | 2016 | 1255 | 0.310 |
Why?
|
| Radiosurgery | 1 | 2015 | 1349 | 0.300 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2020 | 8671 | 0.270 |
Why?
|
| Liver Neoplasms | 2 | 2021 | 4091 | 0.260 |
Why?
|
| Cholangiocarcinoma | 2 | 2020 | 519 | 0.260 |
Why?
|
| Bile Duct Neoplasms | 2 | 2020 | 573 | 0.250 |
Why?
|
| Isocitrate Dehydrogenase | 2 | 2019 | 832 | 0.250 |
Why?
|
| Transcription Factors | 1 | 2021 | 12047 | 0.210 |
Why?
|
| Levulinic Acids | 1 | 2020 | 20 | 0.210 |
Why?
|
| Mutation | 3 | 2020 | 29441 | 0.210 |
Why?
|
| Phosphofructokinase-1 | 1 | 2019 | 53 | 0.200 |
Why?
|
| Protoporphyrins | 1 | 2020 | 166 | 0.200 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2020 | 726 | 0.170 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2016 | 8925 | 0.160 |
Why?
|
| Azepines | 1 | 2018 | 339 | 0.150 |
Why?
|
| Biliary Tract Surgical Procedures | 1 | 2016 | 49 | 0.150 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2019 | 621 | 0.150 |
Why?
|
| Anorexia | 1 | 2016 | 159 | 0.140 |
Why?
|
| Prothrombin | 1 | 2015 | 192 | 0.140 |
Why?
|
| Japan | 1 | 2020 | 1365 | 0.140 |
Why?
|
| alpha-Fetoproteins | 1 | 2015 | 220 | 0.140 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2016 | 11317 | 0.130 |
Why?
|
| Organoids | 1 | 2020 | 651 | 0.130 |
Why?
|
| Dilatation, Pathologic | 1 | 2016 | 516 | 0.130 |
Why?
|
| Photochemotherapy | 1 | 2020 | 829 | 0.130 |
Why?
|
| Hepatocytes | 1 | 2021 | 1249 | 0.120 |
Why?
|
| Laparotomy | 1 | 2016 | 473 | 0.120 |
Why?
|
| Nausea | 1 | 2016 | 658 | 0.120 |
Why?
|
| Triazoles | 1 | 2018 | 922 | 0.110 |
Why?
|
| Logistic Models | 2 | 2020 | 13594 | 0.110 |
Why?
|
| Protein Precursors | 1 | 2015 | 1190 | 0.100 |
Why?
|
| DNA Damage | 1 | 2021 | 2467 | 0.100 |
Why?
|
| Chromatin | 1 | 2021 | 2730 | 0.100 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2021 | 2970 | 0.100 |
Why?
|
| Abdominal Pain | 1 | 2016 | 1028 | 0.090 |
Why?
|
| Mice, Knockout | 2 | 2020 | 15263 | 0.080 |
Why?
|
| Equipment Design | 1 | 2015 | 3628 | 0.080 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2016 | 3555 | 0.080 |
Why?
|
| Thrombosis | 1 | 2020 | 2852 | 0.080 |
Why?
|
| Bone Density | 1 | 2020 | 3411 | 0.080 |
Why?
|
| Intestines | 1 | 2016 | 1934 | 0.080 |
Why?
|
| Radiation Dosage | 1 | 2015 | 2038 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 6779 | 0.060 |
Why?
|
| Aged, 80 and over | 3 | 2020 | 58503 | 0.060 |
Why?
|
| Apoptosis | 1 | 2021 | 10111 | 0.060 |
Why?
|
| Mice | 5 | 2021 | 80997 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 1 | 2020 | 22941 | 0.050 |
Why?
|
| Multivariate Analysis | 1 | 2015 | 12477 | 0.050 |
Why?
|
| Proportional Hazards Models | 1 | 2015 | 12404 | 0.050 |
Why?
|
| Neoplasm Staging | 1 | 2015 | 11191 | 0.050 |
Why?
|
| Ketoglutaric Acids | 1 | 2019 | 80 | 0.050 |
Why?
|
| Tumor Microenvironment | 2 | 2022 | 3072 | 0.050 |
Why?
|
| Humans | 10 | 2022 | 715118 | 0.050 |
Why?
|
| Treatment Outcome | 2 | 2016 | 62186 | 0.050 |
Why?
|
| Citric Acid Cycle | 1 | 2019 | 230 | 0.040 |
Why?
|
| Glutarates | 1 | 2019 | 230 | 0.040 |
Why?
|
| Animals | 5 | 2021 | 170733 | 0.040 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2018 | 297 | 0.040 |
Why?
|
| Aged | 3 | 2020 | 162672 | 0.040 |
Why?
|
| Female | 5 | 2020 | 377328 | 0.040 |
Why?
|
| Mice, Inbred NOD | 1 | 2020 | 1922 | 0.040 |
Why?
|
| Middle Aged | 3 | 2020 | 214868 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2020 | 2840 | 0.030 |
Why?
|
| Autophagy | 1 | 2022 | 1345 | 0.030 |
Why?
|
| Gene Silencing | 1 | 2021 | 1615 | 0.030 |
Why?
|
| Cell Line, Tumor | 2 | 2022 | 16939 | 0.030 |
Why?
|
| Male | 4 | 2020 | 351080 | 0.030 |
Why?
|
| Time Factors | 1 | 2015 | 41082 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2015 | 20397 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2020 | 3693 | 0.030 |
Why?
|
| Adult | 2 | 2016 | 212128 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2018 | 4353 | 0.020 |
Why?
|
| Risk Factors | 1 | 2015 | 70705 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2015 | 34394 | 0.020 |
Why?
|
| Cell Survival | 1 | 2018 | 6131 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2015 | 72253 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2018 | 10799 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2019 | 12425 | 0.010 |
Why?
|
| Prognosis | 1 | 2020 | 29167 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2020 | 39285 | 0.010 |
Why?
|